

Plant-production biotech company BioStrategies LC wins research grant

April 8, 2013

BioStrategies LC has received a \$290,000 Small Business Innovation Research Phase I grant from the U.S. National Institutes of Health to develop an Enzyme Replacement Therapy for Sanfilippo A Lysosomal Rare Disease.

The Arkansas-based company has previously won several SBIR grants, from the NIH as well as the U.S. Department of Agriculture. This small company is devoted to the development of innovative biotechnologies and products to exploit the advantages of plants for production and delivery of products to improve human and animal health.

BioStrategies LC will use the latest SBIR grant to fund the development of a new ERT technology for MPS IIIA, a disease with tremendous unmet patient needs.

This new grant will serve to increase the company's effort in finding new and improved therapeutics for lysosomal diseases.

Contacts:

David Radin, Ph.D.

Managing Director, BioStrategies LC

870-8978-7310; www.biostrategies-lc.com